[Vronchiolitis and its treatment].
Bronchiolitis is the most common lower respiratory tract illness of infancy and is primarily caused by an infection with the respiratory syncytial virus (RSV). An inadequately elevated hospitalisation rate and the use of different treatments with unproven efficacy lead to high cost in terms of public health. Implementation of evidence based guidelines can reduce these costs but not parents satisfaction and quality of care. Palivizumab is a preventive medication with specific indications. Post-bronchiolitis bronchial hyperreactivity has been demonstrated, particularly if the first episode required hospital admission. However, no medication has proven its efficacy to reduce this postbronchiolitis hyperreactivity.
de Bilderling
Georges
G
Service de pédiatrie Cliniques UCL Mont-Godinne. georges.debilderling@pedi.ucl.ac.be
D016535:Bronchial Hyperreactivity / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D001988:Bronchiolitis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D001993:Bronchodilator Agents / Q000627:therapeutic use; D006801:Humans
D001993:Bronchodilator Agents